AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00826618 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ranibizumab
Description: This is an open-label, Phase I study of intravitreally administered 0.5mg ranibizumab in subjects with uveitic CME.
Study NCT04668066 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo given intravenously or subcutaneous
Study NCT01107665 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pazopanib and Paclitaxel
Description: Paclitaxel will be administered intravenously at a starting dose of 80mg/m2 weekly for 3 weeks followed by a 1-week rest. Pazopanib will be administered orally, in a continuous regimen, with a starting dose of 800mg daily.
Study NCT03325959 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hyperbaric oxygen therapy (HBOT) treatment
Description: 60 HBOT sessions at 2 ATA 100% oxygen
Study NCT03325959 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cymbalta / Lyrica treatment
Description: one of the two medications currently licensed for the treatment of FMS in Israel, i.e. Cymbalta and Lyrica.
Study NCT03325959 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Crossover Hyperbaric oxygen therapy
Description: 60 HBOT sessions at 2 ATA 100% oxygen after crossover
Study NCT01103388 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: 375 mg/m\^2 by vein (IV) in 4 weekly doses (1 cycle) every 6 months for 4 cycles.
Study NCT04499560 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Supplement Drink
Description: Superfoods based nutritional supplement
Study NCT03609411 — intervention group
Intervention type: PROCEDURE
Intervention: Splenectomy
Description: Splenectomy was performed after hepatectomy, in an extra-hilar manner with manual ligation of splenic vessels.
Study NCT03060200 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Self-administered online CBT plus therapist check in
Description: The app being tested is comprised of courses, exercises and a behavioural activation component. Courses represent the psycho-educational background of the program, comprising topics such as: information on depression, what is CBT, healthy/unhealthy negative emotions, rational/irrational thoughts, behaviour, social support, relaxation techniques, sleep hygiene, relapse prevention, treatment adherence, and suicide prevention plan. Exercises use the information presented in the courses and follow the structure of a regular therapy session/ therapeutic homework. The following exercises are included in the app: Emotional Pulse, Find Irrational Thoughts, and Change Irrational Thoughts. The behavioural activation component consists in two main exercises: My goals and My Activities.
Study NCT03060200 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Sham self-administered online CBT plus therapist check in
Description: The active placebo intervention will be delivered via the same platform and largely in the same format as the tested app: it will include the same sections and features as the original app, except for the complete exercises. In addition, the psychoeducation section, although mirroring the structure of the corresponding section in the original app, will include different content, elaborating on common sense psychological well being aspects.
Study NCT00665535 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Turning or repositioning schedule
Description: Turning schedule randomly assigned at 2, 3, or 4 hours
Study NCT01097174 — intervention group
Intervention type: DEVICE
Intervention: CyPass Micro-Stent
Description: The CyPass Micro-Stent is a small tube with a through-lumen designed to redirect aqueous fluid from the front into the back of they eye.
Study NCT01530776 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Healthy Lifestyle Group
Description: Electronically-mediated, behavioral intervention during and after pregnancy encouraging mothers to eat healthy, exercise, and return to their early pregnancy weights by 1 year postpartum
Study NCT00949624 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Intravenous 100 mg/m2 every three weeks
Study NCT00949624 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AG-013736
Description: Oral tablet 5 mg BID continuous
Study NCT02733510 — intervention group
Intervention type: DRUG
Intervention: methylprednisolone
Description: Steroid pulse therapy : Methylprednisolone 0.5 g daily for 3 days, followed by a tapered dose of 60 mg per day for a period of five days.
Study NCT00706836 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pregabalin 50mg
Description: One dose of oral pregabalin (50 mg) to be administered one hour prior to fMRI scan
Study NCT00706836 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pregabalin 200 MG
Description: One dose of oral pregabalin (200 mg) to be administered one hour prior to fMRI scan
Study NCT00706836 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: One dose of matched oral placebo to be administered one hour prior to fMRI scan
Study NCT00544076 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sildenafil citrate
Description: Given orally
Study NCT00544076 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sildenafil citrate
Description: Given orally
Study NCT00544076 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: alprostadil
Description: Given intraurethrally
Study NCT00544076 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: robotic-assisted laparoscopic surgery
Description: Undergo prostatectomy
Study NCT00544076 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: robotic-assisted laparoscopic surgery
Description: Undergo prostatectomy
Study NCT00544076 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: quality-of-life assessment
Description: Ancillary studies
Study NCT00889863 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: canakinumab
Description: Canakinumab 4 mg/kg dose subcutaneous injection supplied as 6 mL glass vials each containing 150 mg canakinumab as a lyophilized cake.
Study NCT00889863 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo powder matching canakinumab supplied as 6 mL glass vials containing a lyophilized cake for subcutaneous injection every 4 weeks in Part II.
Study NCT04554615 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin
Description: insulin infusion to control postoperative hyperglycemia
Study NCT00665535 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Turning or repositioning schedule
Description: Turning schedule randomly assigned at 2, 3 or 4 hours
Study NCT03406780 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CAP-1002
Description: The active pharmaceutical ingredient in CAP-1002 is Cardiosphere-Derived Cells (CDCs). CDCs are known to secrete numerous bioactive elements (growth factors, exosomes) which impact the therapeutic benefits of the cell-based therapy. The mechanism of action is the composite ability to be immunomodulatory, anti-fibrotic and regenerative.
Study NCT00962325 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention to increase physical activity
Description: This will be a 6-week preoperative intervention to increase structured walking activity. This will be accomplished through weekly individual face-to-face sessions involving tailored instruction in use of standard behavior change strategies such as self-monitoring, goal-setting, stimulus control, etc.
Study NCT00978146 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxyurea
Description: Patients will take oral hydroxyurea with a starting dose of 20 mg/kg daily. Patients will remain on hydroxyurea as long as there is a response or stability in tumor size and associated toxicities are manageable. Maximum treatment duration will be one year.
Study NCT01325688 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEP005 (ingenol mebutate) Gel, 0.05%
Description: PEP005 (ingenol mebutate) Gel, 0.05% for up to three consecutive days
Study NCT01325688 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Aluminium disk
Study NCT01325688 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OpSite(TM) disk
Study NCT00544076 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: quality-of-life assessment
Description: Ancillary studies
Study NCT02279095 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palovarotene dose level 1
Description: Palovarotene was taken orally once daily at approximately the same time each day.
Study NCT00544076 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: questionnaire administration
Description: Ancillary studies
Study NCT00544076 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: questionnaire administration
Description: Ancillary studies
Study NCT02279095 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palovarotene dose level 2
Description: Palovarotene will be taken orally once daily at approximately the same time each day.
Study NCT02279095 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palovarotene dose level 3
Description: Palovarotene will be taken orally once daily at approximately the same time each day.
Study NCT02279095 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palovarotene dose level 4
Description: Palovarotene will be taken orally once daily at approximately the same time each day.
Study NCT03475485 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ID-Capsule- Active
Description: A standard gelatin or HPMC capsule with an embedded ingestible wireless sensor.
Study NCT03475485 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Wearable Sensor
Description: Subjects will wear an ID-Reader
Study NCT03475485 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Wearable Sensor
Description: Subjects will wear an ID-Reader
Study NCT03406780 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT03475485 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A standard gelatin or HPMC capsule without an embedded ingestible wireless sensor.
Study NCT04205682 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabidiol
Description: CBD capsules administered BD for 4-days (800-1200 mg/day), placebo day 5
Study NCT04205682 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsules administered BD for 5 days
Study NCT00881348 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LACTIC ACID(ND)
Description: Dermacyd infantile (Lactic Acid)
Study NCT03487744 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Osmolite 1.5
Description: Continuous enteral tube feeding according to a standardized calculation via nasojejunal tube.
Study NCT03487744 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Promote without fiber
Description: Continuous enteral tube feeding according to a standardized calculation via nasojejunal tube.
Study NCT03949608 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: E-learning
Description: The intervention consists of the presentation and installation of an internet tool to educate the patient about his heart condition and about his medications in addition to usual care. The tool is an interactive web-hosting video called Mon Coeur, mon BASIC adaptable to smartphones and tablets. The total length of the video is around 15 minutes. The e-learning is interactive because of the possibility to click in the video to have more details about a particular point. The tool includes a part about the heart and particularly about the ACS (physiopathology, diagnosis, coronarography, angioplasty). A second part includes an education about the medications prescribed. The patient will select the medication being prescribed and receive information about it.
Study NCT03517761 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bone Marrow Concentrate treatment
Description: While under unconscious TIVA anesthesia, the injectate is then injected under fluoroscopy into the area in need of treatment using an anterior approach through the posterior oropharynx with direct visualization of the injection site via endoscopy. The alar, transverse, and accessory ligaments are the target areas to be treated with the bone marrow concentrate injectate. Patients will be repositioned in the prone position to then receive upper cervical injections to C0-C3 ligaments and facets.Patients will receive 2 of these treatment procedures 3 months apart.
Study NCT03517761 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham Control
Description: Control subjects will receive a sham procedure of a small skin puncture to the posterior oropharynx guided under fluoroscopy while under anesthesia.Patients will also receive small skin punctures to the back of the neck to mimic ligament and facet injections. Patients will receive 2 of these procedure 3 months apart.
Study NCT03319823 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thiazide Treatment Group
Description: Thiazide Treatment Group: Non-diabetics with sleep systolic blood pressure of 125-139 mm Hg and awake systolic blood pressure \<160 mm Hg Participants will be treated with Indapamide 0.625mg once a day After 4 weeks of treatment, the investigators will monitor chemistries/electrolytes with a fingerstick point of care device and repeat ambulatory blood pressure monitoring the investigators will repeat ambulatory blood pressure monitoring at 4, 8, and 12 weeks after treatment initiation.~If sleep systolic blood pressure is \< 120 mm Hg, the investigators will continue treatment
Study NCT03319823 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intensified Thiazide Treatment Group
Description: At 4 weeks of therapy, individuals initially assigned to the Thiazide treatment group whose ambulatory blood pressure recheck showed a sleep systolic blood pressure >120 mm Hg, the investigators will intensify their blood pressure medications by adding on Telmisartan 40 mg and Amlodipine 5 mg. In two week intervals, labs and ambulatory blood pressure will be measured. If the systolic blood pressure >120, then the doses of Telmisartan and Amlodipine will be up-titrated until the sleep systolic blood pressure is \<120.
Study NCT03319823 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combination Medication Treatment Group
Description: Combination Medication Treatment Group: Diabetics or sleep systolic blood pressure of ≥ 140 mm Hg, or awake systolic blood pressure of ≥ 160 mm Hg~* Participants will be treated with starting doses of a long acting blood pressure regimen of Telmisartan 40 mg and Amlodipine 5 mg daily~* After 2 weeks, the investigators will monitor chemistries/electrolytes with a fingerstick point of care device and repeat ambulatory blood pressure monitoring~  * If sleep systolic blood pressure is \< 120 mm Hg, the investigators will continue treatment and repeat ambulatory blood pressure again in another 2 weeks to assess reproducibility~ * If sleep systolic blood pressure is > 120 mm Hg, the investigators will increase Telmisartan dose to 80 mg and the Amlodipine dose to 10 mg. Ambulatory blood pressure monitoring will be checked again after 2 weeks of therapy to verify efficacy.
Study NCT01435486 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Caffeine citrate
Description: Single stat dose (25 mg per kilogram of body weight) of intravenous caffeine citrate (25mg caffeine citrate equal to 12.5mg caffeine base).
Study NCT01435486 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: Placebo with an equivalent volume of normal saline.
Study NCT04265417 — intervention group
Intervention type: PROCEDURE
Intervention: Robotic Assisted Rectal Cancer Resection Alone
Description: participants in this group underwent robotic assisted rectal cancer resection alone, the specimens were extracted through the incision on the abdominal wall.
Study NCT01763606 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enoxaparin
Description: Patients will be receive 6 months of subcutaneous enoxaparin (1 mg/kg BID with a maximum starting dose of 100 mg BID. Patients who weigh more than 100 kg will start at a dose of 100 mg BID; their subsequent dosing will be guided by hematology and may change.
Study NCT01763606 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Description: Patients will receive 6 months of oral aspirin (81 mg per day unless a higher dose is preferred by study physicians although the maximum acceptable dose will be 325 mg per day).
Study NCT02449161 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MPA
Study NCT02449161 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study NCT02451020 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Altitude exposure
Description: Participants will stay for 3 weeks at an altitude of 3200 m
Study NCT01959841 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP2151
Description: 200 mg once daily or 400 mg once daily
Study NCT01959841 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: valaciclovir
Description: 1000 mg three times daily
Study NCT02005588 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: amino acid chelated iron
Description: the drug will be given to pregnant women 14-18 weeks' gestation who prove to have iron deficiency anemia. the dose will be given according to hemoglobin level. for hemoglobin 7-9 g/dl, 2 capsules will be given daily. for hemoglobin 9.1-11 g/dl, 1 capsule will be given daily. complete blood picture and serum ferritin will be measured at 22-23, 29-30 and 36-37 weeks' gestation.
Study NCT02005588 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: iron salt (ferrous fumarate)
Description: this drug will be given to pregnant women 14-18 weeks' gestation with iron deficiency anemia. the dose will be given according to hemoglobin level. for hemoglobin 7-9 g/dl, 2 capsules will be given daily, and for hemoglobin 9.1-11 g/dl, 1 capsule will be given daily. complete blood picture and serum ferritin will be measured at 22-23, 29-30 and 36-37 weeks' gestation.
Study NCT01400568 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LPS challenge with nebulized LPS
Description: 20,000 EU of Clinical Center Reference Endotoxine (CCRE) will be applied by an AKITA® Jet Nebulizer under the constant supervision of the site staff.
Study NCT01400568 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluticasone propionate (FP)
Description: The dosage of FP will be 2 mg. This dosage will be inhaled by 4 puffs of Flutide® forte 500 Diskus® 500 µg / dose according to the package insert.
Study NCT05095259 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: insulin human
Description: Hyperinsulinemic glucose clamp studies require that insulin is administered at a steady continuous rate to achieve stable levels of hyperinsulinemia. To reach this, insulin needs to be infused intravenously using a standard intravenous pump system. The insulin dose will be adjusted according to the body surface area, aiming for insulin levels of \~170 mIU/l, which is within the physiological range. Thus, for a subject with a bodyweight of 70 kg, body length of 180 cm and - consequently - a body surface area of 1.936 m2, the required insulin infusion can be calculated as: 1.936 x 60 x 60 ÷ 1000 = 7.0 units per hour
Study NCT05095259 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin human
Description: Hyperinsulinemic glucose clamp studies require that insulin is administered at a steady continuous rate to achieve stable levels of hyperinsulinemia. To reach this, insulin needs to be infused intravenously using a standard intravenous pump system. The insulin dose will be adjusted according to the body surface area, aiming for insulin levels of \~170 mIU/l, which is within the physiological range. Thus, for a subject with a bodyweight of 70 kg, body length of 180 cm and - consequently - a body surface area of 1.936 m2, the required insulin infusion can be calculated as: 1.936 x 60 x 60 ÷ 1000 = 7.0 units per hour
Study NCT05095259 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epinephrin
Description: Epinephrine are prepared in 100 ml isotone saline solution according to weight and infused in 3 different infusion rates: 10 ng∙kg-1∙min-1, 25 ng∙kg-1∙min-1 and 50 ng∙kg-1∙min-1, for 20 minutes each. After each adrenaline infusion, substrate response will be measured by blood samples of glucose, lactate, free fatty acids, alanine, β-hydroxybutyrate, glycerol and insulin. Furthermore, cardiovascular measurements such as pulse and blood pressure are monitored as well.
Study NCT05095259 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epinephrin
Description: Epinephrine are prepared in 100 ml isotone saline solution according to weight and infused in 3 different infusion rates: 10 ng∙kg-1∙min-1, 25 ng∙kg-1∙min-1 and 50 ng∙kg-1∙min-1, for 20 minutes each. After each adrenaline infusion, substrate response will be measured by blood samples of glucose, lactate, free fatty acids, alanine, β-hydroxybutyrate, glycerol and insulin. Furthermore, cardiovascular measurements such as pulse and blood pressure are monitored as well.